MedTrace Logo

A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic Dermatitis

NCT02583022 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2015-10-21

No results posted yet for this study

Summary

The study is a Phase II, single center, randomized, open-label, placebo-controlled study in male and female subjects, aged ≥ 20 years with mild to moderate atopic dermatitis. All subjects will receive BID topical applications of PAC-14028 cream or vehicle or Elidel cream for up to 4 weeks.

Conditions

Interventions

DRUG

PAC-14028 cream 1.0%

Topical application

DRUG

PAC-14028 cream vehicle

Topical application

DRUG

Elidel cream 1%

Topical application

Sponsors & Collaborators

  • Amorepacific Corporation

    lead INDUSTRY

Principal Investigators

  • BeomJoon Kim, Professor · Department of Dermatology, Chungang University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-01-31
Completion
2015-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02583022 on ClinicalTrials.gov